Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Victorian Clinical Genetics Services, |
RCV002470546 | SCV002768703 | pathogenic | Kleefstra syndrome 2 | 2023-07-16 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Kleefstra syndrome 2 (MIM#617768). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0701 - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. More than 10 other NMD-predicted variants have previously been reported as pathogenic in patients with Kleefstra syndrome (ClinVar, DECIPHER). (SP) 0802 - This variant has moderate previous evidence of pathogenicity in an unrelated individual. This variant has been reported as pathogenic, heterozygous and de novo (unconfirmed parentage) in an individual in DECIPHER with limited phenotypic information provided. (SP) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1203 - This variant has been shown to be de novo in the proband (parental status confirmed, by trio analysis). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |
| Laboratory of Genetics, |
RCV004731274 | SCV005044949 | likely pathogenic | KMT2C-related NDD | criteria provided, single submitter | research |